Seeking Alpha

Biogen (BIIB) agrees to acquire Stromedix, a privately-held developer of treatments for fibrosis...

Biogen (BIIB) agrees to acquire Stromedix, a privately-held developer of treatments for fibrosis and organ failure, for $75M in cash and potential additional payments of up to $487.5M. Stromedix's most advanced candidate, STX-100, is a monoclonal antibody that has shown promise in early stage trials to treat fibrosis. BIIB -0.5% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)